Redefining Psoriatic Care: New Data, New Standards

Lindsay Ackerman, MD, discusses how advancements in biologic and small molecule therapies are redefining treatment goals and patient outcomes in moderate to severe psoriasis.

Lindsay Ackerman, MD, explores key clinical and patient-centered factors guiding therapy selection in psoriasis management.

Lindsay Ackerman, MD, examines how comparative and real-world data inform treatment decisions and shape confidence in long-term management strategies.

Lindsay Ackerman, MD, discusses how efficacy, safety, and patient suitability differ between oral agents and advanced biologics for psoriasis.

Lindsay Ackerman, MD, outlines how clinicians balance efficacy, tolerability, and patient preference when initiating first-line therapy.

Lindsay Ackerman, MD, highlights clinical strategies for addressing psoriasis in challenging or visible areas such as the scalp, nails, and genitals.

Lindsay Ackerman, MD, provides insights into optimizing sequencing strategies when patients fail to achieve desired outcomes with oral treatments.

Lindsay Ackerman, MD, discusses how biologic selection can be tailored based on disease distribution, symptom burden, and patient quality-of-life goals.

Lindsay Ackerman, MD, critiques traditional clinical trial models and proposes ways to improve their relevance to real-world patient populations.

Lindsay Ackerman, MD, explores novel agents and the potential of biomarkers to personalize treatment selection in psoriasis.